Delcath Systems, Inc. (NASDAQ- DCTH) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. Our proprietary product---Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure.
Delcath is in late-stage clinical development in the United States with initial commercial activities in Europe, where the Melphalan/HDS is marketed as a CE Marked device under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). Our commercial strategy for CHEMOSAT is to steadily grow clinical adoption in major European markets and utilize physician experience to support appeals for reimbursement. Since launch over 250 CHEMOSAT treatments have been performed at over 20 leading European cancer centers. In 2016, we launched our FOCUS Pivotal Study in Hepatic Dominant Ocular Melanoma, and are investigating orphan indications in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. We believe Melphalan/HDS is uniquely positioned to treat the entire liver as a stand-alone or complementary therapy.
Company Details
- Employees
- 111
- Founded
- -
- Address
- 1633 Broadway, 22nd Floor,suite C,ireland
- Phone
- 2124892102
- me****@****ath.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- delcath.com
- Keywords
- Oncology, Research & Development, Liver Cancers, Ocular Melanoma, Intrahepatic cholangiocarcinoma, Hepatocellular carcinoma, Uveal Melanoma, Metastatic Uveal Melanoma, Hepatic dominant uveal melanoma, Liver directed therapy.
- HQ
- New York, NY
Delcath Systems Questions
Delcath Systems's helpline number is 2124892102
Delcath Systems's website is delcath.com
Delcath Systems's LinkedIn profile is https://www.linkedin.com/company/delcath-systems-inc
Delcath Systems has
111 employees.
View email and phone details for 111
employees at Delcath Systems.
Delcath Systems's industry is
Pharmaceutical Manufacturing
Delcath Systems's top competitors are
Kingdom Supercultures,
Envisagenics,
Immunic Therapeutics,
Aethon Therapeutics,
Protara Therapeutics,
Nuvation Bio,
Lexeo Therapeutics,
Biospherix, Llc,
Oncusp Therapeutics,
Transcend Therapeutics.
Delcath Systems's support email address is medaffairs@delcath.com
Delcath Systems's categories are Pharmaceutical Manufacturing
Delcath Systems's founding year is 1987
